Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates

A. Azzi, S. Ciappi, K. Zakvrzewska, M. Morfini, G. Mariani, P. M. Mannucci

Research output: Contribution to journalArticle

Abstract

Human parvovirus B19 can be transmitted by coagulation factor concentrates and is highly resistant to virucidal methods. To evaluate whether the additional removal of virus by chromatographic methods during the manufacture of highly-purity concentrates reduces the risk of B19 transmission, we have prospectively evaluated the rate of anti-B19 seroconversion in two groups of susceptible (anti-B19 negative) hemophiliacs infused with high-purity, heated (pasteurized) or solvent-detergent-treated factor VIII concentrates. Both products infected a relatively high proportion of patients (nine of 20).

Original languageEnglish
Pages (from-to)228-230
Number of pages3
JournalAmerican Journal of Hematology
Volume39
Issue number3
Publication statusPublished - 1992

Keywords

  • anti-B19
  • Coagulation factor concentrates
  • Virucidal methods

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates'. Together they form a unique fingerprint.

  • Cite this